Cardiovascular Benefits of Omega-3 Polyunsaturated Fatty Acids: Volume 7 Solvay Pharmaceuticals Conferences

196 Pages·2007·2.49 MB·English

by  B. Maisch

CARDIOVASCULAR BENEFITS OF OMEGA-3
POLYUNSATURATED FATTY ACIDS
Solvay Pharmaceuticals Conferences
Series Editors
Werner Cautreels, Claus Steinborn and Lechoslaw Turski
Volume 7
Previously published in this series
Vol. 6 B. Testa and L. Turski (Eds.), Virtual ADMET Assessment in Target Selection and
Maturation
Vol. 5 C.G. Kruse, H.Y. Meltzer, C. Sennef and S.V. van de Witte (Eds.), Thinking About
Cognition: Concepts, Targets and Therapeutics
Vol. 4 J. Antel, N. Finer, D. Heal and G. Krause (Eds.), Obesity and Metabolic Disorders
Vol. 3 G. Krause, J.R. Malagelada and U. Preuschoff (Eds.), Functional Disorders of the
Gastrointestinal Tract
Vol. 2 J.G. Papp, M. Straub and D. Ziegler (Eds.), Atrial Fibrillation: New Therapeutic
Concepts
Vol. 1 E. Ronken and G.J.M. van Scharrenburg (Eds.), Parkinson’s Disease
ISSN 1566-7685
Cardiovascular Benefits of Omega-3
Polyunsaturated Fatty Acids
Edited by
B. Maisch
Philipps University of Marburg, Marburg, Germany
and
R. Oelze
Solvay Pharmaceuticals, Hannover, Germany
Amsterdam • Berlin • Oxford • Tokyo • Washington, DC
© 2006 The authors.
All rights reserved. No part of this book may be reproduced, stored in a retrieval system,
or transmitted, in any form or by any means, without prior written permission from the publisher.
ISBN 978-1-58603-707-9
Library of Congress Control Number: 2006939183
Publisher
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
Netherlands
fax: [phone]
e-mail: [email protected]
Distributor in the UK and Ireland Distributor in the USA and Canada
Gazelle Books Services Ltd. IOS Press, Inc.
White Cross Mills 4502 Rachael Manor Drive
Hightown Fairfax, VA 22032
Lancaster LA1 4XS USA
United Kingdom fax: [phone]
fax: [phone] e-mail: [email protected]
e-mail: [email protected]
LEGAL NOTICE
The publisher is not responsible for the use which might be made of the following information.
PRINTED IN THE NETHERLANDS
Cardiovascular Benefits of Omega-3 Polyunsaturated Fatty Acids v
B. Maisch and R. Oelze (Eds.)
IOS Press, 2006
© 2006 The authors. All rights reserved.
Preface
“The Solvay Pharmaceutical Conferences:
where industry meets academia in a search for novel therapies”
Therapy for Sudden Death Still Awaited
During the last decades progress has been made in the treatment of patients who survived
myocardial infarction. The implementation of coronary care units and evolution of public
education to encourage rapid response, development of catheter-based revascularization
techniques, greater emphasis on cardiac rehabilitation, and improved therapy have
contributed to improvement of prognosis for patients with myocardial infarction. The
introduction of aspirin, thrombolytics, ß-blockers, ACE-inhibitors and statins led to
reduction in both short-term and immediate mortality rates among patients suffering from
myocardial infarction. Nevertheless, patients who survive an acute myocardial infarction
are at high risk, with life expectancy half that of their peers who have not experienced similar
events, and with increased risk for subsequent cardiovascular events and death. The risk of
sudden death increases with severity of systolic dysfunction after myocardial infarction.
Sudden death has proved to be more difficult to treat than coronary disease.
In recent years, it has become clear that in addition to risk factors such as
overweight, lack of exercise, smoking, hypertension and hypercholesterolemia,
psychosocial factors play a key role for prognosis in patients with myocardial infarction.
Depression, anxiety, perceived social support and social desirability may have an effect on
mortality and morbidity in such patients. Therefore, there is high medical need for drugs
which lower the incidence of sudden death and have an effect on other risk factors such as
depression.
A pharmaceutical preparation of highly purified and concentrated (cid:58)-3
polyunsaturated acids, OMACOR®, may represent such a drug. It lowers the incidence of
sudden death in patients with myocardial infarction and decreases depression.
This volume summarizes lectures delivered during the symposium entitled “Effect
of (cid:58)-3 polyunsaturated fatty acids on different risk factors in patients with cardiovascular
disease” presented during the European Cardiology Society Congress in Stockholm
(Sweden) in 2005. In addition, aspects of prevention of cardiovascular disease, risk factors,
and pharmacokinetics of (cid:58)-3 fatty acids ethyl esters have been considered.
W. Cautreels
C. Steinborn
L. Turski
This page intentionally left blank
vii
List of Contributors
Alter, P.
Molecular Cardiology Laboratory, Department of Internal Medicine and Cardiology,
Philipps University of Marburg, Karl-von-Frisch-Strasse 1, D-35033 Marburg,
Germany
Annemans, L.
HEDM-IMS, Rue De Crayer 6, 1000 Brussels, Belgium
Ghent University, Sint-Pietersnieuwstraat 25, 9000 Ghent, Belgium
Cautreels, W.
Solvay Pharmaceuticals, Brussels, Belgium
Connolly, S.J
Faculty of Health Sciences, McMaster University, 237 Barton Street E., Hamilton,
Ontario L8L 2X2, Canada
Frasure-Smith, N.
Centre Hospitalier de l’Université de Montréal, Hôpital Notre-Dame, Recherche
Psychiatrie, Pavillon L-C Simard, 1560 rue Sherbrooke Est, Montréal, Québec, Canada
H2L 4M1
Healey, J.S.
Faculty of Health Sciences, McMaster University, 237 Barton Street E., Hamilton,
Ontario L8L 2X2, Canada
Huber, G.
1st Medical Department, SMZ-Ost/Danube Hospital, Langobardenstrasse 122, A-1220
Vienna, Austria
Kawalec, P.
HTA Center, Nuszkiewicza Street 13/19, Krakow, Poland
Institute of Public Health, Collegium Medium, Jagiellonian University, Grzegorzecka
Street 20, Krakow, Poland
Lamotte, M.
HEDM-IMS, Rue De Crayer 6, 1000 Brussels, Belgium
Lespérance, F.
Centre Hospitalier de l’Université de Montréal, Hôpital Notre-Dame, Recherche
Psychiatrie, Pavillon L-C Simard, 1560 rue Sherbrooke Est, Montréal, Québec, Canada
H2L 4M1
viii
Maisch, B.
Molecular Cardiology Laboratory, Department of Internal Medicine and Cardiology,
Philipps University of Marburg,Baldingerstrasse, D-35043 Marburg, Germany
Rupp, H.
Molecular Cardiology Laboratory, Department of Internal Medicine and Cardiology,
Philipps University of Marburg, Karl-von-Frisch-Strasse 1, D-35033 Marburg,
Germany
Rupp, T.P.
Molecular Cardiology Laboratory, Department of Internal Medicine and Cardiology,
Philipps University of Marburg, Karl-von-Frisch-Strasse 1, D-35033 Marburg,
Germany
Selimi, D.
1st Medical Department, SMZ-Ost/Danube Hospital, Langobardenstrasse 122, A-1220
Vienna, Austria
Severus, W.E.
Ludwig-Maximilians-University, Department of Psychiatry, Nußbaumstrasse 7, 80336
Munich, Germany
Steinborn, C.
Solvay Pharmaceuticals, Hannover, Germany
Turski, L.
Solvay Pharmaceuticals, Weesp, The Netherlands
Verboom, C.N.
Solvay Pharmaceuticals, Hannover, Germany
Vik, H.
Pronova Biocare, P.O. Box 420, N-1327 Lysaker, Norway
Vinereanu, D.
University of Medicine and Pharmacy Carol Davila, Cardiology, University Hospital of
Bucharest, Splaiul Independentei 169, Bucharest, 05098, Romania
Wagner, D.
Molecular Cardiology Laboratory, Department of Internal Medicine and Cardiology,
Philipps University of Marburg, Karl-von-Frisch-Strasse 1, D-35033 Marburg,
Germany
Weber, H.S.
1st Medical Department, SMZ-Ost/Danube Hospital, Langobardenstrasse 122, A-1220
Vienna, Austria
Zoellner, Y.
Solvay Pharmaceuticals GmbH, Global Health Economics, P.O. Box 220, D-30002
Hannover, Germany
ix
Contents
Preface v
W. Cautreels, C. Steinborn and L. Turski
List of Contributors vii
Conference Preface 3
Bernhard Maisch
Keynote Lecture – Risk Factors for Atherosclerotic Disease: Present and Future 7
Dragos Vinereanu
Microdetermination of Fatty Acids by Gas Chromatography and Cardiovascular
Risk Stratification by the “EPA+DHA Level” 47
Heinz Rupp, Thomas P. Rupp, Daniela Wagner, Peter Alter and
Bernhard Maisch
Highly Purified Omega-3 Polyunsaturated Fatty Acids Are Effective as Adjunct
Therapy for Secondary Prevention of Myocardial Infarction: Critical Analysis
of GISSI-Prevenzione Trial 81
Cees N. Verboom
Prevention of Cardiovascular Diseases and Highly Concentrated n-3
Polyunsaturated Fatty Acids (PUFAs) 99
Heinz S. Weber, Dzevair Selimi and Gustav Huber
Omega-3 Fatty Acids and Sudden Arrhythmic Death 111
Stuart J. Connolly and Jeffrey S. Healey
Depression and Coronary Artery Disease: Epidemiology and Potential
Mechanisms 121
Nancy Frasure-Smith and François Lespérance
Effects of Omega-3 Polyunsaturated Fatty Acids on Depression 129
W. Emanuel Severus
A Multi-Country Health-Economic Evaluation of Highly Concentrated n-3
Polyunsaturated Fatty Acids (PUFAs) in the Secondary Prevention After
Myocardial Infarction (MI) 139
Mark Lamotte, Lieven Annemans, Pawel Kawalec and York Zoellner
®
OMACOR in Clinical Development: A Survey of Current Trials 155
Hogne Vik
Author Index 185
This page intentionally left blank